Mr Tong Kooi Ong
Chairman, Independent and Non-Executive Director
The business, the people and the ownership behind Thomson Medical.
Business overview
Thomson Medical operates healthcare businesses in Singapore, Malaysia and Vietnam. Its services include healthcare for women and children, specialist clinics and multidisciplinary hospital services.
Listed security
Board & management
FY2026 annual report snapshot. Group CEO Dr Heng Jun Li Melvin and Group CFO Wilson Sam retained as issuer executive roles; outside-company roles not substituted. Seven directors and ten company/contact disclosures from original corporate directory.
Chairman, Independent and Non-Executive Director
Executive Vice-Chairman
Executive Director and Group Chief Executive Officer
Executive Director and Group Chief Financial Officer
Non-Independent and Non-Executive Director; Audit and Risk Committee member; Nominating and Remuneration Committee member
Independent Director; Nominating and Remuneration Committee Chairman; Audit and Risk Committee member
Independent Director; Audit and Risk Committee Chairman; Nominating and Remuneration Committee member
101 Thomson Road #20-04/05 United Square Singapore 307591
+65 6331 0188
+65 6331 0180
www.thomsonmedicalgroup.com
Ms Foo Soon Soo; Ms Seah Sin Yuen
B.A.C.S. Private Limited; 77 Robinson Road #06-03 Robinson 77 Singapore 068896
Ernst & Young LLP; One Raffles Quay North Tower Level 18 Singapore 048583
Ms Peh Sharon; appointed in FY2026
Malayan Banking Berhad; Standard Chartered Bank; United Overseas Bank Limited
Roles listed in Thomson Medical Group Limited Annual Report 2026; current appointments are not independently verified.
Holdings
Raffles Nominees reported0.09%, while25,142,000 dividedby26,443,616,207 rounds0.10%; original inconsistency retained and qualified.
Snapshot14September2026; issuedordinaryshares26,443,616,207, treasuryNil, subsidiaryholdingsNil; publicfloat10.17%;top20total25,189,318,373shares95.26%.
Registered/nominee holdings do not establish ultimate beneficial ownership; do not sum them with deemed interests.
Lim Eng Hock deemed interest includes shares registered to Jovina Investments Limited, Bellton International Limited, Garville Pte Ltd and Meriton Capital Limited, and shares held through nominees, as original footnote.
Direct interest: 9,826,470,334 shares (37.16%); deemed interest: 13,910,365,393 shares (52.60%)
Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. PDF p. 216
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| LIM ENG HOCK | 37.16% | 9,826,470,334 | PDF p. 216 |
| UOB KAY HIAN PTE LTD | 30.04% | 7,944,972,460 | PDF p. 216 |
| DB NOMINEES (SINGAPORE) PTE LTD | 18.91% | 5,000,020,000 | PDF p. 216 |
| CITIBANK NOMINEES SINGAPORE PTE LTD | 5.95% | 1,573,196,099 | PDF p. 216 |
| DBS NOMINEES PTE LTD | 0.83% | 218,325,744 | PDF p. 216 |
| BNP PARIBAS NOMINEES SINGAPORE PTE LTD | 0.61% | 162,250,000 | PDF p. 216 |
| GARVILLE PTE LTD | 0.42% | 111,930,588 | PDF p. 216 |
| PHILLIP SECURITIES PTE LTD | 0.27% | 70,897,617 | PDF p. 216 |
| OCBC SECURITIES PRIVATE LTD | 0.18% | 48,675,720 | PDF p. 216 |
| MOOMOO FINANCIAL SINGAPORE PTE LTD | 0.15% | 39,736,718 | PDF p. 216 |
| CGS INTERNATIONAL SECURITIES SINGAPORE PTE LTD | 0.11% | 27,856,500 | PDF p. 216 |
| RAFFLES NOMINEES (PTE) LIMITED | 0.09% | 25,142,000 | PDF p. 216 |
| UNITED OVERSEAS BANK NOMINEES PTE LTD | 0.09% | 24,405,562 | PDF p. 216 |
| MAYBANK SECURITIES PTE LTD | 0.09% | 23,081,800 | PDF p. 216 |
| OCBC NOMINEES SINGAPORE PTE LTD | 0.08% | 21,134,420 | PDF p. 216 |
| IFAST FINANCIAL PTE LTD | 0.07% | 18,058,511 | PDF p. 216 |
| LIM AND TAN SECURITIES PTE LTD | 0.06% | 15,104,800 | PDF p. 216 |
| TANG CHONG SIM | 0.06% | 14,796,200 | PDF p. 216 |
| CHUA LEONG HAI @ CHUA LEANG HAI | 0.05% | 12,000,000 | PDF p. 216 |
| HSBC (SINGAPORE) NOMINEES PTE LTD | 0.04% | 11,263,300 | PDF p. 216 |
Group structure
Original Notes16–18 disclose21significant subsidiaries, oneassociate andonejointventure; significant list is not represented as alllegal entities.
Ownership percentages follow original immediate holding paths; 100% owned subsidiaries below70.13%TMC Life Sciences are not claimed100%ultimately owned byTMG.
Hatch Health is inprocessofstrikeoff but remains disclosed50%jointventure; do not treatzerocarryingvalue asnoownership. Aspire associate40%is separately classified despitezero/less1000carryingamount.
| Company | Market | Ownership interest |
|---|---|---|
| Sasteria Pte LtdPDF p. 188 | Singapore; Investment holding; held through Company; disclosed ownership FY2026 100%, FY2025 100% | |
| Vantage Bay JB Sdn BhdPDF p. 188 | Malaysia; Leasing of property and investment holding; held through Company; disclosed ownership FY2026 100%, FY2025 100% | |
| Sasteria (VN) Pte LtdPDF p. 188 | Singapore; Investment holding; held through Company; disclosed ownership FY2026 100%, FY2025 100% | |
| Sasteria (M) Pte LtdPDF p. 188 | Singapore; Investment holding; held through Sasteria Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| Thomson Medical Pte LtdPDF p. 188 | Singapore; Operates a hospital; held through Sasteria Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| Thomson Paediatric Centre Pte LtdPDF p. 188 | Singapore; Operates specialist paediatric medical clinics; held through Thomson Medical Pte Ltd; disclosed ownership FY2026 80%, FY2025 80% | |
| Thomson Women’s Clinic Holdings Pte LtdPDF p. 188 | Singapore; Operates specialist medical clinics; held through Thomson Medical Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| Thomson Fertility Centre Pte LtdPDF p. 188 | Singapore; Operates specialist medical clinics; held through Thomson Medical Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Life Sciences BerhadPDF p. 188 | Malaysia; Investment holding; held through Sasteria (M) Pte Ltd; disclosed ownership FY2026 70.13%, FY2025 70.13% | |
| Thomson Hospitals Sdn BhdPDF p. 188 | Malaysia; Multi-disciplinary tertiary care services; held through TMC Life Sciences Berhad; disclosed ownership FY2026 100%, FY2025 100% | |
| BB Waterfront Sdn BhdPDF p. 188 | Malaysia; Provision of healthcare services; held through TMC Life Sciences Berhad; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Fertility Holdings Sdn BhdPDF p. 188 | Malaysia; Investment holding; held through TMC Life Sciences Berhad; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Women’s Specialist Holdings Sdn BhdPDF p. 188 | Malaysia; Operating fertility centres and providing related services; held through Thomson Hospitals Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| IVF Technologies Sdn BhdPDF p. 189 | Malaysia; Provision of fertility services and operation of women’s clinic; held through TMC Fertility Holdings Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Lifestyle Sdn BhdPDF p. 189 | Malaysia; Development, marketing and management of healthcare programmes; fertility consultancy, laboratory and embryology services and research and development; held through TMC Fertility Holdings Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Fertility (Ipoh) Sdn BhdPDF p. 189 | Malaysia; Provision of fertility services and operation of women’s clinic; held through TMC Fertility Holdings Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Fertility (Penang) Sdn BhdPDF p. 189 | Malaysia; Provision of fertility services and operation of women’s clinic; held through TMC Fertility Holdings Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| TMC Fertility South Sdn BhdPDF p. 189 | Malaysia; Provision of fertility services and operation of women’s clinic; held through TMC Fertility Holdings Sdn Bhd; disclosed ownership FY2026 100%, FY2025 100% | |
| FVH Singapore Pte LtdPDF p. 189 | Singapore; Investment holding; held through Sasteria (VN) Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| Far East Medical Vietnam LimitedPDF p. 189 | Vietnam; Provision of hospital and dispensary services; held through FVH Singapore Pte Ltd; disclosed ownership FY2026 100%, FY2025 100% | |
| American Chiropractic ClinicPDF p. 189 | Vietnam; Medical services of chiropractic and nutritional counselling; held through Far East Medical Vietnam Limited; disclosed ownership FY2026 100%, FY2025 100% | |
| Aspire Surgery Centre Pte LtdPDF p. 193 | Singapore; Specialised medical services, clinic services and other general medical services; held through Thomson Medical Pte Ltd; disclosed ownership FY2026 40%, FY2025 –; Cost and share of results marked less thanSGD1000; Group carrying amount dash after unrecognised netliability adjustment | |
| Hatch Health Pte LtdPDF p. 191 | Singapore; Development of software and application; held through Thomson X Pte Ltd; disclosed ownership FY2026 50%, FY2025 50%; In process of strike off; carrying amount FY2026 dash, FY2025 SGD17thousand | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Ms Loh Wei Ning Cassandra | Acting Chief Executive Officer, Thomson Medical Singapore | Thomson Medical Singapore | PDF p. 19 |
| Dr Patricia Mary Hogan | Chief Operating Officer, Thomson Medical Singapore | Thomson Medical Singapore | PDF p. 19 |
| Mr Kan Kheong Ng | Executive Vice-Chairman; TMC Life Sciences Berhad | TMC Life Sciences Berhad | PDF p. 20 |
| Dato’ Dr Ahmad Adzuan Bin Abdul Rahman | Group Chief Executive Officer, TMC Life Sciences Berhad, and Regional Senior Director, Thomson Medical Group | TMC Life Sciences Berhad; Thomson Medical Group | PDF p. 20 |
Extracted from Thomson Medical Group Limited Annual Report 2026 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Interested Person Transactions | IPTs did not exceed $100,000 during FY2026 | Group, FY2026 | PDF p. 129 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Secured bank loans | corporate guarantees provided by the Company and subsidiaries of the Company | Company bank loans, FY2026 · As at 2026-06-30 | PDF p. 200 |
| Bank loans of the subsidiaries | $281,142,000 | Subsidiaries bank loans, 2026 (2025: $277,056,000) · As at 2026-06-30 | PDF p. 200 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Lim Wee Kiat(2) | 1,109 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Dr Heng Jun Li Melvin | 1,181 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Wilson Sam | 797 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Tong Kooi Ong(3) | – $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Ng Ser Miang(4) | 51 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Ong Pang Liang | 69 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Christina Teo Tze Wei | 62 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| June Leong Lai Ling | 120 $'000 | FY2026, individual director, Total column | PDF p. 118 |
| Between $750,000 and $1,000,000 | 1 executives | FY2026, KMP excluding Directors/GCEO, Number of Executives | PDF p. 119 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Permanent | 2,229.3 FTE | Group, FY2026, Total Female; Total Male is 685.6 | PDF p. 94 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Subsequent events | On 2 July 2026, Far East Medical Vietnam Limited (“FEMVN”), a wholly owned subsidiary of the Group, entered into an uncommitted revolving loan facility with an aggregate principal amount of up to US$1.0 million | Group · As at 2026-07-02 | PDF p. 215 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Description and location | Land under development in Malaysia’s Iskandar Development Region | Group, 30 June 2026 · As at 2026-06-30 | PDF p. 195 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Chairman's Statement | The next phase in Singapore is therefore focused on increasing utilisation, strengthening referral flows between specialties and improving returns on our existing infrastructure and human capital. | Singapore, Chairman | PDF p. 8 |
Extracted from Thomson Medical Group Limited Annual Report 2026 and checked against the cited pages; see the original report for full context.
Corporate information